RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
RenaissThera Private Limited (“RenaissThera“), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR).




